Novartis has finally given up on iscalimab after deciding that the anti-CD40 antibody is not worth pursuing in Sjögren’s syndrome. | Novartis has finally given up on iscalimab after deciding that the ...

A webcast replay will be accessible following the live session on the Company’s website under Events.

Eledon Pharmaceuticals has a promising anti-CD40L antibody for organ rejection prevention in transplantation. Learn more ...

The drug candidate is a humanized anti-CD40L monoclonal antibody. It acts by targeting CD40 ligand (CD40L) and is administered through intravenous and subcutaneous routes. The drug candidate was also ...

近年来，CD40和CD40L逐渐走入科研的前沿，成为免疫系统研究的重要焦点。作为一种跨膜蛋白，CD40在抗原呈递细胞表面大放异彩，尤其在B细胞、巨噬 ...

近年来，CD40和CD40L逐渐走入科研的前沿，成为免疫系统研究的重要焦点。作为一种跨膜蛋白，CD40在抗原呈递细胞表面大放异彩，尤其在B细胞、巨噬细胞以及树突状细胞的激活过程中发挥关键作用。而其配体CD40L则主要依托于活化T细胞的表面，二者的相互作用在 ...

CD40–CD40L signaling may regulate both the initiation and effector phases of B- and T-cell responses, as well as transmigration of activated cells to target tissues. Direct therapy against this ...

which is an Fc-modified humanized monoclonal antibody targeting CD40-ligand (CD40L or CD154) being developed for the prevention of allograft rejection and for the treatment of autoimmune diseases.

The firm’s compound in development is AT-1501, a humanized IgG1 anti-CD40L antibody with high affinity for CD40 ligand (CD40L, also called CD154), a well-validated biological target with broad ...

Scientists from the Miller School of Medicine at the University of Miami have reported their recent work to develop small-molecule inhibitors of the CD40-CD40L (CD154) costimulatory protein-protein ...

1. Introduction The trans-membrane molecule CD40 has attracted attention as a therapeutic target in CLL [1]. Within the haematopoietic system the CD40-CD40 ligand (CD40L) interaction plays a central ...